Brokerage firm, Canaccord Genuity Group Inc., is paying US$75 million to settle allegations from U.S. regulators that, due to deficiencies in its compliance systems and controls, the firm failed to ...

Jack Henry® (Nasdaq: JKHY) announced today that Jack Henry Financial Crimes Defender™ has been added to the Independent Community Bankers of America® (ICBA) Preferred Service Provider (PSP) program.

Investors are monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor, Guenther Koehne, is set to deliver opening remarks. ・The Phase 3 Regal trial evaluating ...

Coinbase faces shareholder lawsuit over custody disclosures, token listings, & AML compliance, spotlighting governance risks.

KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions –– Market feedback emphasizes differentiated ...

Federal prosecutors charge Paxful founder Ray Youssef as company pleads guilty to money laundering and prostitution-related ...

ThetaRay, a global leader in Cognitive AI financial crime compliance, and Matrix USA, a premier global service integrator of anti-money laundering (AML), financial crime and compliance systems, today ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Bank of America is replacing its Preferred Rewards program with a new, expanded program called BofA Rewards. The new program eliminates the minimum balance requirement for initial enrollment, making ...

Add Yahoo as a preferred source to see more of our stories on Google. Eric Wear, owner of Extreme Window Systems, installs impact doors and windows at the home of Jeff Torrey in Deerfield Beach as ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ...

Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform.